Filing Flows › Atara Biotherapeutics (ATRA) › R&D spending
Atara Biotherapeutics (ATRA) R&D spending by quarter
Atara Biotherapeutics' R&D spending was $1.3M in Q2 2026 (second quarter 2026), +720% from Q1 2026. Over the last 6 quarters it ranged from $164K (Q1 2026) to $28.7M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $1.3M | +720% | -82% |
| Q1 2026 | $164K | -94% | -99% |
| Q3 2025 | $2.9M | -60% | — |
| Q2 2025 | $7.3M | -73% | — |
| Q1 2025 | $27.4M | -4% | — |
| Q4 2024 | $28.7M | — | — |
Q2 2026 at a glance
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Atara Biotherapeutics' R&D spending?
Atara Biotherapeutics' R&D spending was $1.3M in Q2 2026 (second quarter 2026), +720% from Q1 2026.
How has Atara Biotherapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $164K (Q1 2026) to $28.7M (Q4 2024).